Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1672
    +0.0016 (+0.13%)
     

  • GBP/USD

    1.2481
    -0.0030 (-0.24%)
     

  • Bitcoin GBP

    51,055.78
    -307.66 (-0.60%)
     

  • CMC Crypto 200

    1,321.55
    -74.99 (-5.37%)
     

  • S&P 500

    5,102.54
    +54.12 (+1.07%)
     

  • DOW

    38,243.79
    +157.99 (+0.41%)
     

  • CRUDE OIL

    84.10
    +0.53 (+0.63%)
     

  • GOLD FUTURES

    2,348.40
    +5.90 (+0.25%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

BUZZ-AstraZeneca: top FTSE 100 gainer on lung cancer drug hopes

Reuters - UK Focus

** AstraZeneca (NYSE: AZN - news) top FTSE 100 gainer, up 0.6% in sharply lower market, after Jefferies calls out multibillion-dollar potential of durvalumab plus tremelimumab combination immunotherapy in lung cancer

** Price target upgraded to £58 a share from £54

** Broker (4 stars for recommendation accuracy on AZN, per StarMine) sees up to 39% upside for shares if closely watched MYSTIC clinical trial hits its goal vs 10% downside if it fails. Results from MYSTIC expected any time from February 2017

** Success could drive peak annual sales opportunity for durvalumab and tremelimumab of around $7.9 bln in non-small cell lung cancer (NSCLC), with more potentially from other combinations and adjuvant NSCLC, Jefferies says (Other OTC: UBGXF - news)